OncoMatch/Clinical Trials/NCT07252739
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Is NCT07252739 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for malignant neoplasm.
Treatment: MK-1084 · Pembrolizumab · Cetuximab · Carboplatin · Pemetrexed — Researchers want to learn if using a study medicine called MK-1084 can help treat NSCLC. MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: KRAS g12c mutation
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: systemic anticancer therapy
Has received prior systemic anticancer therapy for advanced or metastatic NSCLC
Cannot have received: KRAS inhibitor
Has received previous treatment with an agent targeting KRAS
Lab requirements
Cardiac function
No uncontrolled, clinically significant cardiovascular disease or cerebrovascular disease, including NYHA Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, QTcF >470 ms, or other serious cardiovascular/cerebrovascular diseases within 6 months
uncontrolled, clinically significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of corrected QT interval corrected for heart rate by Fridericia's formula (QTcF) interval to >470 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clermont Oncology Center ( Site 0041) · Clermont, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify